BiotechTube
Renexxion

Renexxion

Dublin, Ireland· Est.
rnexltd.ie
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $65M

Overview

Renexxion is a clinical-stage biotech company advancing naronapride (ATI-7505), a minimally absorbable, dual-mechanism (5-HT4 agonist/D2 antagonist) prokinetic drug candidate for major GI disorders with high unmet need. Its lead program is in a global Phase 2b trial for gastroparesis with partner Dr. Falk Pharma, with a Phase 2b in PPI-non-responsive GERD planned for 2026. The company is privately held, backed by a $100M investment commitment, and has built a robust IP portfolio around its compound.

Gastrointestinal

Technology Platform

Dual-mechanism (5-HT4 agonist / D2 antagonist), minimally absorbable small molecule prokinetic designed for local gut activity.

Funding History

2
Total raised:$65M
Series B$40M
Series A$25M

Opportunities

The addressable market is vast, with over 100 million patients globally needing a safe prokinetic.
Success in gastroparesis or PPI-non-responsive GERD, each representing multi-billion dollar segments, could position naronapride as a foundational therapy.
The 'pipeline-in-a-product' strategy allows efficiency in developing one compound for multiple high-need indications.

Risk Factors

The company faces binary clinical risk as its value hinges on Phase 2b trial outcomes for its single asset.
Regulatory hurdles are high for GI motility drugs, particularly regarding cardiac safety.
Commercial success depends on effective execution by its partner and future build-out of its own capabilities.

Competitive Landscape

The GI motility space is competitive but marked by high unmet need and historical safety failures. Competitors include other 5-HT4 agonists (e.g., prucalopride for constipation), newer ghrelin agonists, and neuromodulators for gastroparesis. Naronapride's dual mechanism and localized action aim to differentiate it on efficacy and tolerability.

More companies in Small Molecule Drugs →More companies in Ireland →